Publications

Celemics’ Publications

Science is a collaborative process which works best when new knowledge is shared.
We contribute to this by presenting our research at scientific congresses and publishing our results in scientific journals.

Application

  • (25)
  • (3)
  • (54)
  • (14)
  • (19)
  • (85)
  • (48)
  • (4)
  • (31)

Date

  • (10)
  • (9)
  • (10)
  • (12)
  • (21)
  • (23)
  • (38)
  • (67)
  • (50)
  • (24)
  • A humanized ACE2 mouse model recapitulating age- and sex-dependent immunopathogenesis of COVID-19 (9/25/2024) Posted in: Others

    Journal of Medical Virology

    A humanized ACE2 mouse model recapitulating age- and sex-dependent immunopathogenesis of COVID-19

    Park U, Lee JH, Kim U, Jeon K, Kim Y, Kim H, Kang JI, Park MY, Park SH, Cha JS, Yoon GY. A humanized ACE2 mouse model recapitulating age‐and sex‐dependent immunopathogenesis of COVID‐19. Journal of Medical Virology. 2024 Sep;96(9):e29915.

     

    10.1002/jmv.29915


    View Detail >

  • A Korean Family Presenting with Renal Cysts and Maturity-Onset Diabetes of the Young Caused by a Novel In-Frame Deletion of HNF1B (9/23/2024) Posted in: Inherited Diseases

    International journal of Molecular Sciences

    A Korean Family Presenting with Renal Cysts and Maturity-Onset Diabetes of the Young Caused by a Novel In-Frame Deletion of HNF1B

    Han JY, Gwack J, Kim TY, Park J. A Korean Family Presenting with Renal Cysts and Maturity-Onset Diabetes of the Young Caused by a Novel In-Frame Deletion of HNF1B. International Journal of Molecular Sciences. 2024 Sep 11;25(18):9823.

     

    10.3390/ijms25189823


    View Detail >

  • A sensorineural hearing loss harboring novel compound heterozygous variant in the TRIOBP gene: A case report (9/23/2024) Posted in: Inherited Diseases

    Heliyon

    A sensorineural hearing loss harboring novel compound heterozygous variant in the TRIOBP gene: A case report

    Rhim JW, Kim DK, Han JY, Park J. A sensorineural hearing loss harboring novel compound heterozygous variant in the TRIOBP gene: A Case report. Heliyon. 2024 Sep 4.

     

    10.1016/j.heliyon.2024.e36717


    View Detail >

  • Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13) (8/26/2024) Posted in: Oncology

    Cancer Research and Treatment

    Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)

    Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.

     

    10.4143/crt.2023.1324


    View Detail >

    Summary | celemics publications


    #Oncology


    #ctDNA Sample


    # AlphaLiquid® 100 Panel

    Purpose

    Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), HER2, and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC).

    Result

    Genomic alteration landscape in circulating tumor DNA analysis according to the progression-free survival (PFS), overall survival (OS), and EGFR/HER2 immunohistochemical expression (n=15).


    Conclusion

    A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.

    Method

    The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.

    Related Product

    Circulating Tumor DNA Panel for 

    Colorectal / Lung / Breast Cancer


    View Detail >

    The circulating tumor DNA (ctDNA) was extracted from the patient’s plasma (10 mL) at two time points (before treatment and at the first response evaluation or end of the treatment). The DNA NGS library and solution-based target enrichment were performed at IMBdx, Inc. (Seoul, Korea), using AlphaLiquid100. The captured DNA libraries were sequenced using the Illumina NovaSeq 6000 platform (Illumina, San Diego, CA) in the 2×150 bp paired-end mode.


    liquid-biopsy

    Colorectal Cancer
    Sensitivity Freq. 0.5% 100%
    Freq. 1.0% 100%
    Specificity 97.9%


    liquid-biopsy

    Breast Cancer
    Sensitivity Freq. 0.5% 94.4%
    Freq. 1.0% 100%
    Specificity 96.3%


    liquid-biopsy

    Lung Cancer
    Sensitivity Freq. 0.5% 100%
    Freq. 1.0% 100%
    Specificity 100%




    Image_blog-Thumbnail_Celemics Contact Us_image_link_Got Questions

  • Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer (8/26/2024) Posted in: Liquid Biopsy

    Annals of Laboratory Medicine

    Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer

    Kim B, Kim Y, Cho JY, Lee KA. Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer. Annals of laboratory medicine. 2024 Mar 1;44(2):164-73.

     

    10.3343/alm.2023.0187


    View Detail >